Just listened to the conference call. Positive call. Meeting with FDA planned early Feb. Confident that data on 36 mo will clear all issues and specifcally concerning cataracts. No fixed cost issues going forward since sales force will not be in place until approval. Marketing variable costs under control. manufacturers addressing cGMP issues; none of which had any direct relationship to this product.